This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Reprints and Permissions Copyright Information Books from ASM Press MicrobeWorld Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Thadepalli, H. Articles by Gollapudi, S. Search for Related Content PubMed PubMed Citation Articles by Thadepalli, H. Articles by Gollapudi, S.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, 03 1997, 583-586, Vol 41, No. 3
Copyright © 1997 by the American Society for Microbiology. All rights reserved.

In vivo efficacy of trovafloxacin (CP-99,217), a new quinolone, in experimental intra-abdominal abscesses caused by Bacteroides fragilis and Escherichia coli

H Thadepalli, U Reddy, SK Chuah, F Thadepalli, C Malilay, RJ Polzer, N Hanna, A Esfandiari, P Brown and S Gollapudi
Department of Medicine, Charles R. Drew University of Medicine and Science, Los Angeles, California 90059, USA.

The efficacy of trovafloxacin in treating Bacteroides fragilis and Escherichia coli infections was investigated and compared to the efficacy of combined clindamycin and gentamicin therapy in an experimental model of intra-abdominal abscesses in rats. Rats were treated with different doses of CP-116,517-27, a parenteral prodrug of trovafloxacin. Response to treatment was evaluated by mortality rate and elimination of infection (cure rate). Mortality in the control group was 85.4%, whereas in rats treated with trovafloxacin, it was close to 0%. The highest cure rate (89.3%) resulted from the administration of 40 mg of CP-116,517-27 per kg of body weight three times a day (TID) for 10 days (equivalent to 18.15 mg of active drug trovafloxacin per rat per day). The therapeutic response with trovafloxacin was comparable to that of a combination therapy of clindamycin (75 mg/kg) plus gentamicin (20 mg/kg) TID (cure rate, 74%; mortality rate, 5%). The measured peak levels of trovafloxacin in serum and abscess pus were 2.6 +/- 0.3 and 5.2 micrograms/ml, respectively. The tumor necrosis factor alpha levels in the untreated animals were high compared to those for rats treated with trovafloxacin or clindamycin plus gentamicin. These results demonstrate that trovafloxacin as a single agent appears to be as successful as clindamycin plus gentamicin in the treatment of experimental intra- abdominal abscesses in rats.

This article has been cited by other articles:

• Weiss, T., Shalit, I., Blau, H., Werber, S., Halperin, D., Levitov, A., Fabian, I. (2004). Anti-Inflammatory Effects of Moxifloxacin on Activated Human Monocytic Cells: Inhibition of NF-{kappa}B and Mitogen-Activated Protein Kinase Activation and of Synthesis of Proinflammatory Cytokines. Antimicrob. Agents Chemother. 48: 1974-1982 [Abstract] [Full Text]  
• Golan, Y., McDermott, L. A., Jacobus, N. V., Goldstein, E. J. C., Finegold, S., Harrell, L. J., Hecht, D. W., Jenkins, S. G., Pierson, C., Venezia, R., Rihs, J., Iannini, P., Gorbach, S. L., Snydman, D. R. (2003). Emergence of fluoroquinolone resistance among Bacteroides species. J Antimicrob Chemother 52: 208-213 [Abstract] [Full Text]  
• Stearne, L. E. T., Gyssens, I. C., Goessens, W. H. F., Mouton, J. W., Oyen, W. J. G., van der Meer, J. W. M., Verbrugh, H. A. (2001). In Vivo Efficacy of Trovafloxacin against Bacteroides fragilis in Mixed Infection with either Escherichia coli or a Vancomycin-Resistant Strain of Enterococcus faecium in an Established-Abscess Murine Model. Antimicrob. Agents Chemother. 45: 1394-1401 [Abstract] [Full Text]  
• Ricci, V., Piddock, L. J. V. (2000). Accumulation of Norfloxacin by Bacteroides fragilis. Antimicrob. Agents Chemother. 44: 2361-2366 [Abstract] [Full Text]  
• Thadepalli, H., Reddy, U., Chuah, S. K., Hanna, N., Rana, G., Gollapudi, S. (2000). Evaluation of trovafloxacin in the treatment of Klebsiella pneumoniae lung infection in tumour-bearing mice. J Antimicrob Chemother 45: 69-75 [Abstract] [Full Text]  
• Kaatz, G. W., Seo, S. M., Aeschlimann, J. R., Houlihan, H. H., Mercier, R.-C., Rybak, M. J. (1998). Efficacy of Trovafloxacin against Experimental Staphylococcus aureus Endocarditis. Antimicrob. Agents Chemother. 42: 254-256 [Abstract] [Full Text]